Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On

Yesterday, Pfizer (PFE) delivered something you’ll rarely see: Its March 20 $29 put had the highest unusual options activity on the day with a Vol/OI (volume-to-open-interest) ratio of 210.16, 35% higher than the Alphabet (GOOG) option in second place. 

Pfizer is one of the most frustrating stocks for bulls. Once upon a time, it was printing money thanks to COVID-19. Now, it can’t get out of the $20s. Its shares are down 59% since the 2021 all-time high of $61.71. For those who don’t own PFE, it’s hard to justify the investment. 

Fundamentals

See More
  • Market Capitalization, $K 143,791,552
  • Shares Outstanding, K 5,685,708
  • Annual Sales, $ 63,627 M
  • Annual Income, $ 8,031 M
  • EBIT $ 18,723 M
  • EBITDA $ 25,736 M
  • 60-Month Beta 0.47
  • Price/Sales 2.32
  • Price/Cash Flow 5.79
  • Price/Book 1.54

Options Overview Details

View History
  • Implied Volatility 26.02% (+0.09%)
  • Historical Volatility 18.79%
  • IV Percentile 59%
  • IV Rank 22.89%
  • IV High 52.17% on 04/10/25
  • IV Low 18.25% on 08/18/25
  • Expected Move (DTE 6) 0.57 (2.24%)
  • Put/Call Vol Ratio 0.64
  • Today's Volume 151,519
  • Volume Avg (30-Day) 145,048
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 3,212,029
  • Open Int (30-Day) 3,201,927
  • Expected Range 24.91 to 26.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.58
  • Number of Estimates 5
  • High Estimate 0.68
  • Low Estimate 0.49
  • Prior Year 0.63
  • Growth Rate Est. (year over year) -7.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.83 +2.62%
on 01/02/26
26.65 -4.39%
on 12/15/25
+0.15 (+0.59%)
since 12/09/25
3-Month
23.91 +6.57%
on 11/10/25
26.65 -4.39%
on 12/15/25
+0.24 (+0.95%)
since 10/09/25
52-Week
20.92 +21.83%
on 04/09/25
27.69 -7.98%
on 10/03/25
-1.38 (-5.14%)
since 01/08/25

Most Recent Stories

More News
Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On

There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at 210.16. In the money by 12.8%, it sets up for a couple of different trading...

GOOG : 329.14 (+0.96%)
PFE : 25.48 (+0.75%)
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025

DGX : 174.44 (-1.86%)
EXAS : 102.11 (+0.32%)
ILMN : 141.07 (-3.26%)
ARVN : 12.07 (-0.90%)
PFE : 25.48 (+0.75%)
QTRX : 8.06 (+23.81%)
Worried About a K-Shaped Economy? Buy This Top Dividend ETF for 2026.

SCHD looks well-positioned to outperform significantly if the economy turns south in 2026.

LMT : 542.92 (+4.72%)
KO : 70.51 (+1.64%)
SCHD : 28.55 (+0.46%)
PEP : 139.91 (+0.39%)
ABBV : 220.08 (-1.81%)
AMGN : 326.10 (-1.21%)
PFE : 25.48 (+0.75%)
BMY : 55.86 (-0.07%)
Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio

- Number of Lawsuits Increases Fivefold to Over 2,100 Since May - FDA Approves Brain Tumour Warning Global pharmaceutical company...

RKT.LN : 6,176.000 (+0.10%)
JNJ : 204.39 (-0.66%)
PFE : 25.48 (+0.75%)
Pfizer's Quarterly Earnings Preview: What You Need to Know

Pfizer will release its fourth-quarter earnings next month, and analysts anticipate a low double-digit profit dip.

XLV : 157.31 (-0.51%)
$SPX : 6,966.28 (+0.65%)
PFE : 25.48 (+0.75%)
2 S&P 500 Stocks with Competitive Advantages and 1 We Avoid

2 S&P 500 Stocks with Competitive Advantages and 1 We Avoid

ROST : 191.44 (+1.15%)
PFE : 25.48 (+0.75%)
AJG : 264.59 (+0.02%)
Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

JNJ : 204.39 (-0.66%)
LLY : 1,063.56 (-1.99%)
ABBV : 220.08 (-1.81%)
GSK : 50.39 (+0.34%)
CSLLY : 58.5300 (-0.43%)
PFE : 25.48 (+0.75%)
SNY : 49.03 (+1.87%)
These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever

With the S&P 500 trading at 26 times forward earnings, valuations are a concern entering 2026. Consider these 3 discounted stocks to insulate your portfolio.

NVDA : 184.86 (-0.10%)
GOOGL : 328.57 (+0.96%)
CMCSA : 28.37 (+0.57%)
T : 23.99 (-0.74%)
MU : 345.09 (+5.53%)
LLY : 1,063.56 (-1.99%)
PFE : 25.48 (+0.75%)
DIS : 115.88 (+1.50%)
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 44th Annual J.P. Morgan...

PFE : 25.48 (+0.75%)
3 Stocks Under $50 with Questionable Fundamentals

3 Stocks Under $50 with Questionable Fundamentals

UBSI : 40.64 (+0.40%)
PX : 10.33 (-1.24%)
PFE : 25.48 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 25.93
2nd Resistance Point 25.74
1st Resistance Point 25.61
Last Price 25.48
1st Support Level 25.29
2nd Support Level 25.10
3rd Support Level 24.97

See More

52-Week High 27.69
Last Price 25.48
Fibonacci 61.8% 25.10
Fibonacci 50% 24.30
Fibonacci 38.2% 23.50
52-Week Low 20.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar